trending Market Intelligence /marketintelligence/en/news-insights/trending/qh_faiilombf-n4rsqan1g2 content esgSubNav
In This List

Pfenex plans common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfenex plans common stock offering

Pfenex Inc. is planning to undertake an offering of its common stock.

The San Diego-based biotechnology company expects to grant the underwriters an option to buy additional shares.

Pfenex intends to use the net proceeds to fund expenses in connection with obtaining regulatory approval, commercialization and launch of its osteoporosis medicine PF708, to conduct ongoing research and development, and for general corporate purposes and working capital.

Barclays Capital Inc. and William Blair & Co. LLC are acting as joint book-running managers for the offering.